Year: 2023

AB “Ignitis grupė” (hereinafter – the Group) publishes its first nine months 2023 interim report, which is attached to this notice, and announces that the Group’s Adjusted EBITDA amounted to EUR 345.3 million and decreased by 3.3% YoY, driven by lower captured electricity prices. Additionally, the Customers & Solutions segment’s result decreased due to lower supply volumes, which were driven by the decreased consumption. The Adjusted EBITDA decrease was partly offset by better result of the Reserve Capacities business segment, which was driven by a utilised option to earn additional return in the market on top of the regulated return by fixing positive forward clean spark spread, and better result of the Networks segment, which increased mainly due to higher RAB. The Green Generation segment remains the largest contributor to Adjusted...

Golden Ocean Group Limited (NASDAQ/OSE: GOGL) (the “Company” or “Golden Ocean”), the world’s largest listed owner of large size dry bulk vessels, today announced its unaudited results for the three and nine months ended September 30, 2023. Highlights Net income of $28.7 million and earnings per share of $0.14 (basic) for the third quarter of 2023, compared with net income of $34.9 million and earnings per share of $0.17 (basic) for the second quarter of 2023. Adjusted EBITDA of $78.9 million for the third quarter of 2023, compared with $80.4 million for the second quarter of 2023. Reported TCE rates for Capesize and Panamax/Supramax vessels of $18,173 per day and $15,389 per day, respectively, and $17,076 per day for the entire fleet in the third quarter of 2023. Entered into back-to-back agreements to buy and sell a Supramax vessel....

The multinational Phase III study is evaluating a new pediatric granulated formulation of leniolisib in children aged 1 to 6 years with APDS, a rare primary immunodeficiency Leiden, The Netherlands, November 21, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM)/(Nasdaq: PHAR) announces that the first patient has been dosed in its Phase III pediatric clinical trial evaluating a new pediatric formulation of the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in children ages one to six years, with activated phosphoinositide 3-kinase delta syndrome (APDS). At sites in the U.S., Japan, and the EU, the single-arm, open-label, multinational clinical trial will evaluate the safety, tolerability, and efficacy of leniolisib in 15 children, one to six years...

Press releaseBrussels, 21 November 2023 – 7:00 Regulated information Nethys confirms to Orange Belgium its intention to convert its stake in VOO into Orange Belgium shares UPDATE Last week, Orange Belgium confirmed that it was in discussions with Nethys about converting its 25% + 1 share in VOO into Orange Belgium shares. This option is available to Nethys as part of the acquisition of VOO by Orange Belgium. After obtaining ENODIA’s agreement, Nethys today officially informed Orange Belgium that it wishes to initiate the process of converting its stake in VOO into Orange Belgium shares. At the end of this process, Nethys would obtain an 11% stake in Orange Belgium and would retain, once in the capital of Orange Belgium, the governance rights associated with its stake in VOO. This transaction will be presented to the Orange Belgium...

Biosimilar Hyrimoz® (adalimumab) citrate-free high-concentration formulation (HCF) indicated for all conditions of reference medicine Humira®*  Hyrimoz® HCF to launch progressively across Europe Hyrimoz® HCF strengthens well-established Sandoz biosimilar immunology portfolio in EuropeBasel, November 21, 2023 – Sandoz, the global leader in generic and biosimilar medicines, today announces the launch of Hyrimoz® (adalimumab) citrate-free high concentration formulation (HCF; 100 mg/mL) in Europe. The medicine will become available to patients progressively across European markets, starting today. Hyrimoz® HCF, like the currently available 50mg/mL version of Hyrimoz®, is indicated for all conditions covered by the reference medicine*: rheumatic diseases, Crohn’s disease, ulcerative colitis, plaque psoriasis, uveitis and hidradenitis...

Verkkokauppa.com Oyj        STOCK EXCHANGE RELEASE                21 November 2023 at 8:30 EET Verkkokauppa.com updates its strategy to accelerate profitable growth Verkkokauppa.com continues as a forerunner in the market with the vision of creating the new normal for buying and owning. With the 2024-2028 strategy, the company aims for faster than the market, annual revenue growth (CAGR) of over 5 percent, an annual operating profit margin of over 5 percent and to reduce fixed costs to less than 10 percent of revenue by the end of 2028. The company’s target is to pay out 60-80 percent of annual net profit in quarterly growing dividends. However, in order to improve the company’s equity ratio, the Board of Directors will propose to the Annual General Meeting 2024 that no dividend be paid on the result for 2023. Cornerstones of the...

Stellantis and CATL Sign Strategic MoU for the Local Supply of LFP Batteries for European MarketThe MoU outlines joint development of a state-of-the-art technology roadmap and future battery value chain opportunities Stellantis and CATL are considering the possibility of a joint investment in the form of a joint venture with equivalent contributions Stellantis aims to leverage lithium iron phosphate (LFP) batteries to power its European electric vehicle production, supporting its aggressive Dare Forward 2030 electrification targetsAMSTERDAM, November 21, 2023 – Stellantis N.V. and CATL today announced the signing of a non-binding Memorandum of Understanding (MoU) for the local supply of LFP battery cells and modules to power Stellantis’ electric vehicle production in Europe. To further support Stellantis’ aggressive electrification...